Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of Laser Treatment of the Crystalline Lens to Correct Presbyopia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects must sign and be given a copy of the written informed consent form.~* Subjects must have elected to undergo lens extraction and IOL implantation to treat their ocular disorder then elect to have the LensAR laser surgery as part of the procedure.~* Cataract should not exceed LOCS III Grade 2.~* Subjects must have best corrected distance visual acuity of 20/40 or better in the eye to be treated .~* Subjects must be ≥ 45 years and ≤ 60 years of age at time of subject eligibility visit.~* Subjects must be willing and able to return for scheduled follow up examinations for 6 months after cataract surgery or up to 3 years (at 6 month intervals) if no cataract surgery is performed.~* Subject must have central 7 mm of clear cornea without vascularization~Exclusion Criteria:~* Subjects who are pregnant, lactating, or planning to become pregnant during the course of the study.~* Subjects who have undergone previous corneal or intraocular surgery in the eye to be treated.~* Subjects with a history, signs or symptoms of ocular disease or atypical finding which would be contraindicated under standard of care for cataract surgery.~* Diabetic or hypertensive subjects with clinical evidence of retinal pathology.~* Subjects with macular degenerative pathology.~* Subjects with a history of steroid-responsive rise in IOP or uncontrolled glaucoma in either eye.~* Subjects with known lens/zonular instability such as, but not restricted to, Marfan's Syndrome, Pseudoexfoliation Syndrome, etc.~* Subjects with corneal disease or pathology that precludes applanation of the cornea or transmission of laser wavelength or distortion of laser light.~* Subjects who cannot attain ocular dilation adequate to allow laser treatment within the minimum range based on the laser procedure to be applied.~* Subjects with known sensitivity to planned study concomitant medications.~* Subjects using systemic medication that is known to reduce the amplitude of accommodation (such as medication for motion sickness containing hyoscine or other antimuscarinic drugs, anticholinergic drugs, anti-psychotic drugs, tricyclic antidepressants and other drugs acting on the central nervous system).~* Subjects participating in any other ophthalmic drug or device clinical trial during the time of this clinical investigation.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).